CONTEMPORARY THERAPEUTIC APPROACHES FOR MULTIPLE MYELOMA

Authors:

Abstract:

This review article analyzes contemporary therapeutic approaches for patients with multiple myeloma. The literature selection was conducted within the Pubmed and Google Scholar databases, encompassing publications from the period of 2020 to 2025. A fundamental principle in the management of multiple myeloma patients is the initial determination of eligibility for autologous hematopoietic stem cell transplantation. Performing autologous hematopoietic stem cell transplantation increases the rate of clinico-hematological remission achievement and improves patient survival outcomes. The development and implementation of novel therapeutic approaches remains a critical focus. Furthermore, enrolling patients in clinical trials is essential, particularly for those with relapsed/refractory multiple myeloma and patients with high-risk disease features. An ongoing area of significant importance is the investigation of supportive care strategies, particularly agents for bone remodeling. This is critically important for improving patient quality of life and reducing the risk of skeletal-related complications.

Keywords:

multiple myeloma chemotherapy treatment autologous hematopoietic stem cell transplantation proteasome inhibitors immunomodulatory drugs monoclonal antibodies

References:

1. Boussi LS, Avigan ZM, Rosenblatt J. Immunotherapy for the treatment of multiple myeloma. Front Immunol. 2022; 13:1027385. doi:10.3389/fimmu.2022.1027385.
2. Chen Y, Tao S, Zheng X, Shi Y, Zhang L, Chen K, et al. Research progress on treatment of extramedullary multiple myeloma. Hematology. 2021; 26(1):985–994. doi:10.1080/16078454.2021.2005310.
3. Clara JA, Childs RW. Harnessing natural killer cells for the treatment of multiple myeloma. Semin Oncol. 2022; 49(1):69–85. doi:10.1053/j.seminoncol.2022.01.004.
4. Côté J, Kotb R, Bergstrom DJ, LeBlanc R, Mian HS, Othman I, et al. First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium. Clinical Lymphoma, Myeloma and Leukemia. 2023; 23(5):340–354. doi:10.1016/j.clml.2023.01.016.
5. Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396(10245):186-197. doi:10.1016/S0140-6736(20)30734-0.
6. Dimopoulos M, Weisel K, Moreau P, Anderson LD Jr, White D, San-Miguel J, et al. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse. Leukemia. 2021;35:1722–1731. doi:10.1038/s41375-020-01021-3.
7. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(3):309–322. doi:10.1016/j.annonc.2020.11.014.
8. Dimopoulos MA, Špička I, Quach H, Oriol A, Hájek R, Garg M, et al. TOURMALINE-MM4 study group. Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. J Clin Oncol. 2020;38(34):4030-4041. doi:10.1200/JCO.20.02060.
9. Engelhardt M, Kortüm KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024; 109(8):2420–2435. doi:10.3324/haematol.2023.283058.
10. Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022;97(1):3-25. doi:10.1002/ajh.26512.
11. Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563-1573. doi:10.1016/S0140-6736(20)32292-3.
12. Gundesen MT, Schjesvold F, Lund T. Treatment of myeloma bone disease: When, how often, and for how long? J Bone Oncol. 2025;52:100680. doi:10.1016/j.jbo.2025.100680.
13. Ho PJ, Li EW. A new era in myeloma: the advent of chimeric antigen receptor-T (CAR-T) cells and bispecific antibodies. Intern Med J. 2025 May;55(5):714-721. doi:10.1111/imj.16647.
14. Holstein SA. Current frontline treatment of multiple myeloma. Oncology (Williston Park). 2022; 36(7):430–441. doi: 10.46883/2022.25920967.
15. Kannan A, Jeffrey K, Misbah S, Ramasamy K. Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach. Blood Rev. 2025:101287. doi:10.1016/j.blre.2025.101287.
16. Kumar S, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto CJ, et al. Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Blood. 2021; 138:84. doi:10.1182/blood-2021-145757.
17. Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, et al. Multiple myeloma, version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023; 21(12):1281–1301. doi:10.6004/jnccn.2023.0061.
18. Lapietra G, Fazio F, Petrucci MT. Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment. Biomolecules. 2022;12(8):1146. doi:10.3390/biom12081146.
19. Lu Q, Yang D, Li H, Niu T, Tong A. Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed. 2024; 5(25). doi:10.1186/s43556-024-00188-w.
20. Maslova GS, Skrypnyk RI, Skrypnyk IN. The role of L-ornithine-L-aspartate in prophylaxis of cytostatic-induced liver injury in patients with multiple myeloma. World Med Biol. 2021; 4(78):100–104. doi:10.26724/2079-8334-2021-4-78-100-104.
21. Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132-141. doi:10.1016/S0140-6736(19)32956-3.
22. Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. The Lancet. 2021;397(10292):2361-2371. doi:10.1016/S0140-6736(21)00592-4.
23. Parikh RH, Lonial S. Chimericantigen receptor T-cell therapy in multiple myeloma: acomprehensive review of current data and implications forclinical practice. CA Cancer J Clin. 2023;73(3):275-285. doi:10.3322/caac.21771.
24. Rafae A, van Rhee F, Al Hadidi S. Perspectives on the Treatment of Multiple Myeloma. The Oncologist. 2024; 29(3):200–212. doi:10.1093/oncolo/oyad306.
25. Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143-e161. doi:10.1016/S2352-3026(21)00283-0.
26. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802-1824. doi:10.1002/ajh.27422.
27. Richardson PG, Kumar SK, Masszi T, Grzasko N, Bahlis NJ, Hansson M, et al. Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2021;39(22):2430-2442. doi:10.1200/JCO.21.00972.
28. Soekojo CY, Chng WJ. Treatment horizon in multiple myeloma. Eur J Haematol. 2022; 109(5):425–440. doi:10.1111/ejh.13840.
29. Terpos E, Rajkumar SV, Leung N. Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination. JAMA Oncol. 2022;8(2):201-202. doi:10.1001/jamaoncol.2021.5942.
30. Testa U, Castelli G, Pelosi E, Galli E, Chiusolo P. Toxicities Associated with CAR-T Cell Therapies. Mediterr J Hematol Infect Dis. 2025;17(1):e2025039. doi: 10.4084/MJHID.2025.039. The Lancet. 2021; 397(10292):2361-2371. doi:10.1016/S0140-6736(21)00592-4.

Publication:

«World of Medicine and Biology» Vol. 22 No. 97 (2026), pp. 243-250
UDC 616-006.448-085

DOI:

https://doi.org/10.26724/2079-8334-2026-3-97-243-250